This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR (July 12): The FBM KLCI reversed its earlier losses and climbed 0.44% at midday break, tracking regional markets, lifted by gains including at banking heavyweights Malayan Banking Bhd and Pulic Bank Bhd.
PBLOF MLYBY SPMXF MLYNF BATS 4162 1295 7153 5168 1155 KLKBY 3204 2445 SPMXY 4456 3301 3867 7205 0026 1899 5819 HRGHY
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819
Kuala Lumpur Kepong Bhd (KLK)’s participation in The Edge Kuala Lumpur Rat Race has become something of an annual tradition since the event kicked off in 2000. This year, it has decided to take its support to the next level by becoming a “Bronze” sponsor.
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF
KUALA LUMPUR: The Malaysian stock market has seen foreign net selling almost on a daily basis since the 14th general election that led to a change of government for the first time in Malaysia’s history, but Rakuten Trade Sdn Bhd is expecting a potential return of foreign funds by the fourth quarter of 2018 (4Q18).
1155 KLKBY 2445 4863 MLYBY MLYNF 5253 MYTEF 0151 GEBHF
KUALA LUMPUR (July 6): The FBM KLCI opened flat this morning, tracking nervy regional markets, ahead of the U.S. deadline to commence to trade tariffs against China.
MLYBY MLYNF UPBMF 2089 7055 7277 1155 KLKBY 2445 3883 5347 TNABY 2836 TNABF
KUALA LUMPUR: The outlook for the second half of the year remains positive with foreign funds expected to return in the fourth quarter, according to Rakuten Trade head of research Kenny Yee.
1155 KLKBY 2445 4863 MLYBY MLYNF 5253 MYTEF 0151 BSMAF GEBHF 1818
KUALA LUMPUR (July 5): The FBM KLCI will benefit when foreign investors return to emerging markets (EM) and when they do, stocks like Malayan Banking Bhd (Maybank), Genting Bhd, Kuala Lumpur Kepong Bhd (KLK) and Telekom Malaysia Bhd (TM) should do well, according to Rakuten Trade Sdn Bhd.
1155 KLKBY 2445 4863 MLYBY MLYNF MYTEF GEBHF
KUALA LUMPUR (July 5): The FBM KLCI hovered above the 1,690-level at mid-morning today, amid some choppy trade as regional markets stayed anxious.
HLFBF PBLOF MLYBY MLYNF UPBMF 1082 1295 3794 2089 1155 KLKBY 2445 3883 4863 6888 5819 AXXTF MYTEF
KUALA LUMPUR (July 4): The FBM KLCI rose at midday break today, lifted by gains at select index-linked blue chips, including Telekom Malaysia Bhd and Axiata Group Bhd, against the backdrop of weaker regional markets.
HLFBF 7084 1082 5031 BATS 4162 1163 0023 KLKBY 2445 4588 4863 5347 3867 0037 0026 TNABY 6888 5819 AXXTF MYTEF TNABF 3719
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719
KUALA LUMPUR (July 4): The FBM KLCI edged up slightly in early trade today, lifted by heavyweights Telekom Malaysia Bhd and Tenaga Nasional Bhd but gains were seen capped in line with the shaky regional markets.
KLKBY 2445 4863 5347 PBLOF TNABY 4405 MYPRY MYTEF TNABF 1295 5014
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET